Experimental combo aims to boost immune attack on sarcoma before surgery

NCT ID NCT04420975

Ongoing Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests the safety of combining two immunotherapy drugs—nivolumab and BO-112—given before surgery for soft tissue sarcoma that can be removed. About 14 adults with certain sarcoma types will receive these drugs to see if they help the immune system fight the tumor more effectively. The main goal is to check for side effects and measure immune changes in the tumor tissue after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEIOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dedifferentiated liposarcoma dermatofibrosarcoma protuberans fibrosarcoma leiomyosarcoma malignant giant cell tumor of soft parts malignant peripheral nerve sheath tumor myxofibrosarcoma neurofibrosarcoma pleomorphic rhabdomyosarcoma retroperitoneal sarcoma sarcoma soft tissue sarcoma spindle cell sarcoma synovial sarcoma undifferentiated high grade pleomorphic sarcoma of bone undifferentiated pleomorphic sarcoma undifferentiated pleomorphic sarcoma, inflammatory variant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEIOMYOSARCOMA MALIGNANT PERIPHERAL NERVE SHEATH TUMOR MYXOFIBROSARCOMA PLEOMORPHIC RHABDOMYOSARCOMA RESECTABLE DEDIFFERENTIATED LIPOSARCOMA RESECTABLE SOFT TISSUE SARCOMA RESECTABLE UNDIFFERENTIATED PLEOMORPHIC SARCOMA SOFT TISSUE FIBROSARCOMA SPINDLE CELL SARCOMA STAGE I RETROPERITONEAL SARCOMA AJCC (AMERICAN JOINT COMMITTEE ON CANCER) V8 STAGE I SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITIES AJCC V8 STAGE IA RETROPERITONEAL SARCOMA AJCC V8 STAGE IA SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITIES AJCC V8 STAGE IB RETROPERITONEAL SARCOMA AJCC V8 STAGE IB SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITIES AJCC V8 STAGE II RETROPERITONEAL SARCOMA AJCC V8 STAGE II SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITIES AJCC V8 STAGE III RETROPERITONEAL SARCOMA AJCC V8 STAGE III SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITIES AJCC V8 STAGE IIIA RETROPERITONEAL SARCOMA AJCC V8 STAGE IIIA SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITIES AJCC V8 STAGE IIIB RETROPERITONEAL SARCOMA AJCC V8 STAGE IIIB SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITIES AJCC V8 STORIFORM-PLEOMORPHIC MALIGNANT FIBROUS HISTIOCYTOMA SYNOVIAL SARCOMA UNDIFFERENTIATED HIGH GRADE PLEOMORPHIC SARCOMA OF BONE UNDIFFERENTIATED PLEOMORPHIC SARCOMA UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH OSTEOCLAST-LIKE GIANT CELLS UNDIFFERENTIATED PLEOMORPHIC SARCOMA, INFLAMMATORY VARIANT UNDIFFERENTIATED SPINDLE CELL SARCOMA

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.